Menu
Back to Journals » Drug Design, Development and Therapy » Volume 17
RETRACTED ARTICLE: 5-Fluorouracil Combined with Rutaecarpine Synergistically Suppresses the Growth of Colon Cancer Cells by Inhibiting STAT3
Authors Yu Z , Chan S, Wang X, Sun R, Wang M , Wang Z, Zuo X , Chen J, Zhang H, Chen W
Received 12 January 2023
Accepted for publication 24 March 2023
Published 30 March 2023 Volume 2023:17 Pages 993—1006
DOI https://doi.org/10.2147/DDDT.S402824
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Anastasios Lymperopoulos
This paper has been retracted.
Yu Z, Chan S, Wang X, et al. Drug Des Devel Ther. 2023;17:993–1006.
At the authors request, the Editor and Publisher of the journal Drug Design, Development and Therapy have retracted the published article.
Following publication of the article, the authors raised concerns about the duplication of images from Figure 4. Specifically,
- The images for Figure 4G, HCT116, RUT and 5-FU, have been duplicated.
The authors wished to apologize for this error and no longer have confidence in the data and corresponding findings. To maintain academic standards, the authors requested to retract the article and the Editor and Publisher agreed with this decision.
We have been informed in our decision-making by our editorial policies and COPE guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.